Epstein-Barr virus-associated Hodgkin's lymphoma

British Journal of Haematology

Volumn 125, Issue 3, 2004, Pages 267-281

  Gandhi, Maher K ^a   Tellam, Judy T ^a   Khanna, Rajiv ^a  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

Epstein Barr virus; Hodgkin's lymphoma; Immunotherapy

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY; TOXIN ANTIBODY;

ADOPTIVE IMMUNOTHERAPY; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER CELL; CANCER CLASSIFICATION; DISEASE ASSOCIATION; DRUG MEGADOSE; EPSTEIN BARR VIRUS; GENE AMPLIFICATION; GENE REARRANGEMENT; GRAFT REJECTION; HISTOPATHOLOGY; HODGKIN DISEASE; HUMAN; LIFE EXPECTANCY; LONG TERMINAL REPEAT; NODULAR LYMPHOMATOSIS; NONHUMAN; NUCLEIC ACID SEQUENCE BASED AMPLIFICATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN TARGETING; REED STERNBERG CELL; REVIEW; T LYMPHOCYTE ACTIVATION; TRANSCRIPTION REGULATION; VIRUS DETECTION; VIRUS ETIOLOGY; VIRUS VIRULENCE;

EPSTEIN-BARR VIRUS INFECTIONS; HODGKIN DISEASE; HUMANS; IMMUNE TOLERANCE; IMMUNOTHERAPY; PROGNOSIS;

EID: 2442478579     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2004.04902.x     Document Type: Review

References (151)

1. Aisenberg, A.C. (1999) Problems in Hodgkin's disease management. Blood, 93, 761-779.
2. Akpek, G., Ambinder, R.F., Piantadosi, S., Abrams, R.A., Brodsky, R.A., Vogelsang, G.B., Zahurak, M.L., Fuller, D., Miller, C.B., Noga, S.J., Fuchs, E., Flinn, I.W., O'Donnell, P., Seifter, E.J., Mann, R.B. & Jones, R.J. (2001) Long-term results of blood and marrow transplantation for Hodgkin's lymphoma. Journal of Clinical Oncology, 19, 4314-4321.
3. Ambinder, R.F. (2000) Gammaherpesviruses and "Hit-and-Run" oncogenesis. American Journal of Pathology, 156, 1-3.
4. Ambinder, R.F., Browning, P.J., Lorenzana, I., Leventhal, B.G., Cosenza, H., Mann, R.B., MacMahon, E.M., Medina, R., Cardona, V., Grufferman, S. (1993) Epstein-Barr virus and childhood Hodgkin's disease in Honduras and the United States. Blood, 81, 462-467.
5. Anderlini, P., Giralt, S., Andersson, B., Ueno, N.T., Khouri, I., Acholonu, S., Cohen, A., Korbling, M.J., Manning, J., Romaguera, J., Sarris, A., Rodriguez, Hagemeister, F., McLaughlin, P., Cabanillas, F. & Champlin, R.E. (2000) Allogeneic stem cell transplantation with fludarabine-based, less intensive conditioning regimens as adoptive immunotherapy in advanced Hodgkin's disease. Bone Marrow Transplantation, 26, 615-620.
6. Asso-Bonnet, M., Feuillard, J., Ferreira, V., Bissieres, P., Tarantino, N., Korner, M. & Raphael, M. (1998) Relationship between Ikappa-Balpha constitutive expression, TNFalpha synthesis, and apoptosis in EBV-infected lymphoblastoid cells. Oncogene, 17, 1607-1615.
7. Axdorph, U., Porwit-MacDonald, A., Sjoberg, J., Grimfors, G., Ekman, M., Wang, W., Biberfeld, P. & Bjorkholm, M. (1999) Epstein-Barr virus expression in Hodgkin's disease in relation to patient characteristics, serum factors and blood lymphocyte function. British Journal of Cancer, 81, 1182-1187.
8. Bargou, R.C., Emmerich, F., Krappmann, D., Bommert, K., Mapara, M.Y., Arnold, W., Royer, H.D., Grinstein, E., Greiner, A., Scheidereit, C. & Dorken, B. (1997) Constitutive nuclear factor-kappaB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells. Journal of Clinical Investigation, 100, 2961-2969.
9. Barth, S., Huhn, M., Matthey, B., Tawadros, S., Schnell, R., Schinkothe, T., Diehl, V. & Engert, A. (2000) Ki-4(scFv)-ETA', a new recombinant anti-CD30 immunotoxin with highly specific cytotoxic activity against disseminated Hodgkin tumors in SCID mice. Blood, 95, 3909-3914.
10. Bierman, P.J., Vose, J.M., Langnas, A.N., Rifkin, R.M., Hauke, R.J., Smir, B.N. & Greiner, T.C. (1996) Hodgkin's disease following solid organ transplantation. Annals of Oncology, 7, 265-270.
11. Blake, N., Haigh, T., Shaka'a, G., Croom-Carter, D. & Rickinson, A. (2000) The importance of exogenous antigen in priming the human CD8+ T cell response: lessons from the EBV nuclear antigen EBNA1. Journal of Immunology, 165, 7078-7087.
12. Bollard, C.M., Rossig, C., Calonge, M.J., Huls, M.H., Wagner, H.J., Massague, J., Brenner, M.K., Heslop, H.E. & Rooney, C.M. (2002) Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity. Blood, 99, 3179-3187.
13. Borchmann, P., Schnell, R., Fuss, I., Manzke, O., Davis, T., Lewis, L.D., Behnke, D., Wickenhauser, C., Schiller, P., Diehl, V. & Engert, A. (2002) Phase 1 trial of the novel bispecific molecule H22xKi-4 in patients with refractory Hodgkin lymphoma. Blood, 100, 3101-3107.
14. Borchmann, P., Treml, J.F., Hansen, H., Gottstein, C., Schnell, R., Staak, O., Zhang, H.F., Davis, T., Keler, T., Diehl, V., Graziano, R.F. & Engert, A. (2003) The human anti-CD30 antibody 5F11 shows in vitro and in vivo activity against malignant lymphoma. Blood, 102, 3737-3742.
15. Brink, A.A., Oudejans, J.J., Jiwa, M., Walboomers, J.M., Meijer, C.J. & van den Brule, A.J. (1997) Multiprimed cDNA synthesis followed by PCR is the most suitable method for Epstein-Barr virus transcript analysis in small lymphoma biopsies. Molecular Cell Probes, 11, 39-47.
16. Chan, K.C., Zhang, J., Chan, A.T., Lei, K.I., Leung, S.F., Chan, L.Y., Chow, K.C. & Lo, Y.M. (2003) Molecular characterization of circulating EBV DNA in the plasma of nasopharyngeal carcinoma and lymphoma patients. Cancer Research, 63, 2028-2032.
17. Chapman, C.J., Zhou, J.X., Gregory, C., Rickinson, A.B. & Stevenson, F.K. (1996) VH and VL gene analysis in sporadic Burkitt's lymphoma shows somatic hypermutation, intraclonal heterogeneity, and a role for antigen selection. Blood, 88, 3562-3568.
18. Chapman, A.L., Rickinson, A.B., Thomas, W.A., Jarrett, R.F., Crocker, J. & Lee, S.P. (2001) Epstein-Barr virus-specific cytotoxic T lymphocyte responses in the blood and tumor site of Hodgkin's disease patients: implications for a T-cell-based therapy. Cancer Research, 61, 6219-6226.
19. Chen, H., Lee, J.M., Zong, Y., Borowitz, M., Ng, M.H., Ambinder, R.F. & Hayward, S.D. (2001) Linkage between STAT regulation and Epstein-Barr virus gene expression in tumors. Journal of Virology, 75, 2929-2937.
20. Clarke, C.A., Glaser, S.L., Dorfman, R.F., Mann, R., DiGiuseppe, J.A., Prehn, A.W. & Ambinder, R.F. (2001) Epstein-Barr virus and survival after Hodgkin disease in a population-based series of women. Cancer, 91, 1579-1587.
21. Clemens, M.J. (1993) The small RNAs of Epstein-Barr virus. Molecular Biology Reports, 17, 81-92.
22. Cobbold, M., Khan, N., Tauro, S., McDonald, D., Ollavaria, E., Chakraverty, R., Goldman, J., Mahendra, P., Craddock, C. & Moss, P. (2003) Phase 1 study of the adoptive transfer of tetramer selected cytomegalovirus- specific cytotoxic T cells after allogeneic stem cell transplantation. British Journal of Haematology, 121, abstract 260.
23. Colby, T.V., Hoppe, R.T. & Warnke, R.A. (1981) Hodgkin's disease at autopsy: 1972-1977. Cancer, 47, 1852-1862.
24. Connors, J.M., Noordijk, E.M. & Horning, S.J. (2001) Hodgkin's lymphoma: basing the treatment on the evidence. In: Hematology (American Society of Hematology Education Program), pp. 178-193. American Society of Hematology, Washington, DC, USA.
25. Cozen, W., Katz, J. & Mack, T.M. (1992) Risk patterns of Hodgkin's disease in Los Angeles vary by cell type. Cancer Epidemiology Biomarkers and Prevention, 1, 261-268.
26. Curtis, R.E., Rowlings, P.A., Deeg, H.J., Shriner, D.A., Socie, G., Travis, L.B., Horowitz, M.M., Witherspoon, R.P., Hoover, R.N., Sobocinski, K.A., Fraumeni, J.F., Jr. & Boice, J.D., Jr. (1997) Solid cancers after Bone Marrow Transplantationation. New England Journal of Medicine, 336, 897-904.
27. Deacon, E.M., Pallesen, G., Niedobitek, G., Crocker, J., Brooks, L., Rickinson, A.B. & Young, L.S. (1993) Epstein-Barr virus and Hodgkin's disease: transcriptional analysis of virus latency in the malignant cells. Journal of Experimental Medicine, 177, 339-349.
28. Delecluse, H.J., Marafioti, T., Hummel, M., Dallenbach, F., Anagnostopoulos, I. & Stein, H. (1997) Disappearance of the Epstein-Barr virus in a relapse of Hodgkin's disease. Journal of Pathology, 182, 475-479.
29. Devergne, O., Hatzivassiliou, E., Izumi, K.M., Kaye, K.M., Kleijnen, M.F., Kieff, E. & Mosialos, G. (1996) Association of TRAF1, TRAF2, and TRAF3 with an Epstein-Barr virus LMP1 domain important for B-lymphocyte transformation: role in NF-kappaB activation. Molecular and Cell Biology, 16, 7098-7108.
30. Diehl, V., Franklin, J., Pfreundschuh, M., Lathan, B., Paulus, U., Hasenclever, D., Tesch, H., Herrmann, R., Dorken, B., Muller-Hermelink, H.K., Duhmke, E. & Loeffler, M. (2003) Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. New England Journal of Medicine, 348, 2386-2395.
31. Dolcetti, R., Frisan, T., Sjoberg, J., De Campos-Lima, P.O., Pisa, P., De Re, V., Gloghini, A., Rizzo, S., Masucci, M.G. & Boiocchi, M. (1995) Identification and characterization of an Epstein-Barr virus-specific T-cell response in the pathologic tissue of a patient with Hodgkin's disease. Cancer Research, 55, 3675-3681.
32. Dolcetti, R., Boiocchi, M., Gloghini, A. & Carbone, A. (2001) Pathogenetic and histogenetic features of HIV-associated Hodgkin's disease. European Journal of Cancer, 37, 1276-1287.
33. Dukers, D.F., Meij, P., Vervoort, M.B., Vos, W., Scheper, R.J., Meijer, C.J., Bloemena, E. & Middeldorp, J.M. (2000) Direct immunosuppressive effects of EBV-encoded latent membrane protein 1. Journal of Immunology, 165, 663-670.
34. Duraiswamy, J., Burrows, J.M., Bharadwaj, M., Burrows, S.R., Cooper, L., Pimtanothai, N. & Khanna, R. (2003a) Ex vivo analysis of T-cell responses to Epstein-Barr virus-encoded oncogene latent membrane protein 1 reveals highly conserved epitope sequences in virus isolates from diverse geographic regions. Journal of Virology, 77, 7401-7410.
35. Duraiswamy, J., Sherritt, M., Thomson, S., Tellam, J., Cooper, L., Connolly, G., Bharadwaj, M. & Khanna, R. (2003b) Therapeutic LMP1 polyepitope vaccine for EBV-associated Hodgkin disease and nasopharyngeal carcinoma. Blood, 101, 3150-3156.
36. Duraiswamy, J., Bharadwaj, M., Tellman, J., Connolly, G., Cooper, L., Moss, D., Thomson, S., Yotnda, P. & Khanna, R. (2004) Induction of therapeutic T-cell responses to subdominant tumor-associated viral oncogene after immunization with replication-incompetent polyepitope adenovirus vaccine. Blood, 64, 1483-1489.
37. Eltringham, J.R. & Kaplan, H.S. (1973) Impaired delayed- hypersensitivity responses in 154 patients with untreated Hodgkin's disease. National Cancer Institute Monographs, 36, 107-115.
38. Enblad, G., Sandvej, K., Lennette, E., Sundstrom, C., Klein, G., Glimelius, B. & Pallesen, G. (1997) Lack of correlation between EBV serology and presence of EBV in the Hodgkin and Reed-Sternberg cells of patients with Hodgkin's disease. International Journal of Cancer, 72, 394-397.
39. Enblad, G., Sandvej, K., Sundstrom, C., Pallesen, G. & Glimelius, B. (1999) Epstein-Barr virus distribution in Hodgkin's disease in an unselected Swedish population. Acta Oncologica, 38, 425-429.
40. Flanagan, J., Middeldorp, J. & Sculley, T. (2003) Localization of the Epstein-Barr virus protein LMP 1 to exosomes. Journal of General Virology, 84, 1871-1879.
41. Flavell, K.J., Biddulph, J.P., Constandinou, C.M., Lowe, D., Scott, K., Crocker, J., Young, L.S. & Murray, P.G. (2000) Variation in the frequency of Epstein-Barr virus-associated Hodgkin's disease with age. Leukemia, 14, 748-753.
42. Flavell, K.J., Billingham, L.J., Biddulph, J.P., Gray, L., Flavell, J.R., Constandinou, C.M., Young, L.S. & Murray, P.G. (2003) The effect of Epstein-Barr virus status on outcome in age- and sex-defined subgroups of patients with advanced Hodgkin's disease. Annals of Oncology, 14, 282-290.
43. Foss, H.D., Reusch, R., Demel, G., Lenz, G., Anagnostopoulos, I., Hummel, M. & Stein, H. (1999) Frequent expression of the B-cell-specific activator protein in Reed-Sternberg cells of classical Hodgkin's disease provides further evidence for its B-cell origin. Blood, 94, 3108-3113.
44. Frisan, T., Sjoberg, J., Dolcetti, R., Boiocchi, M., De Re, V., Carbone, A., Brautbar, C., Battat, S., Biberfeld, P., Eckman, M. (1995) Local suppression of Epstein-Barr virus (EBV)-specific cytotoxicity in biopsies of EBV-positive Hodgkin's disease. Blood, 86, 1493-1501.
45. Gaines, J.D., Gilmer, M.A. & Remington, J.S. (1973) Deficiency of lymphocyte antigen recognition in Hodgkin's disease. National Cancer Institute Monographs, 36, 117-121.
46. Gajewski, J.L., Phillips, G.L., Sobocinski, K.A., Armitage, J.O., Gale, R.P., Champlin, R.E., Herzig, R.H., Hurd, D.D., Jagannath, S., Klein, J.P., Lazarus, H.M., McCarthy, P.L., Jr., Pavlovsky, S., Peterson, F.B., Rowlings, P.A., Russell, J.A., Silver, S.M., Vose, J.M., Wiernik, P.H., Bortin, M.M. & Horowitz, M.M. (1996) Bone Marrow Transplantations from HLA-identical siblings in advanced Hodgkin's disease. Journal of Clinical Oncology, 14, 572-578.
47. Gallagher, A., Armstrong, A.A., MacKenzie, J., Shield, L., Khan, G., Lake, A., Proctor, S., Taylor, P., Clements, G.B. & Jarrett, R.F. (1999) Detection of Epstein-Barr virus (EBV) genomes in the serum of patients with EBV-associated Hodgkin's disease. International Journal of Cancer, 84, 442-448.
48. Gallagher, A., Perry, J., Freeland, J., Alexander, F.E., Carman, W.F., Shield, L., Cartwright, R. & Jarrett, R.F. (2003) Hodgkin lymphoma and Epstein-Barr virus (EBV): no evidence to support hit-and-run mechanism in cases classified as non-EBV-associated. International Journal of Cancer, 104, 624-630.
49. Gan, Y.J., Razzouk, B.I., Su, T. & Sixbey, J.W. (2002) A defective, rearranged Epstein-Barr virus genome in EBER-negative and EBER-positive Hodgkin's disease. American Journal of Pathology, 160, 781-786.
50. Gandhi, M.K., Egner, W., Sizer, L., Inman, I., Zambon, M., Craig, J.I. & Marcus, R.E. (2001) Antibody responses to vaccinations given within the first two years after transplant are similar between autologous peripheral blood stem cell and Bone Marrow Transplantation recipients. Bone Marrow Transplantation, 28, 775-781.
51. Gandhi, M.K., Lekamwasam, S., Inman, I., Kaptoge, S., Sizer, L., Love, S., Bearcroft, P.W., Milligan, T.P., Price, C.P., Marcus, R.E. & Compston, J.E. (2003a) Significant and persistent loss of bone mineral density in the femoral neck after haematopoietic stem cell transplantation: long-term follow-up of a prospective study. British Journal of Haematology, 121, 462-468.
52. Gandhi, M.K., Wills, M.R., Okecha, G., Day, E.K., Hicks, R., Marcus, R.E., Sissons, J.G. & Carmichael, A.J. (2003b) Late diversification in the clonal composition of human cytomegalovirus-specific CD8+ T cells following allogeneic hemopoietic stem cell transplantation. Blood, 102, 3427-3438.
53. Gandhi, M.K., Wills, M.R., Patrick Sissons, J.G. & Carmichael, A.J. (2003c) Human cytomegalovirus-specific immunity following haemopoietic stem cell transplantation. Blood Reviews, 17, 259-264.
54. Glaser, S.L., Lin, R.J., Stewart, S.L., Ambinder, R.F., Jarrett, R.F., Brousset, P., Pallesen, G., Gulley, M.L., Khan, G., O'Grady, J., Hummel, M., Preciado, M.V., Knecht, H., Chan, J.K. & Claviez, A. (1997) Epstein-Barr virus-associated Hodgkin's disease: epidemiologic characteristics in international data. International Journal of Cancer, 70, 375-382.
55. Glaser, S.L., Clarke, C.A., Nugent, R.A., Stearns, C.B. & Dorfman, R.F. (2002) Social class and risk of Hodgkin's disease in young-adult women in 1988-94. International Journal of Cancer, 98, 110-117.
56. Glavina-Durdov, M., Jakic-Razumovic, J., Capkun, V. & Murray, P. (2001) Assessment of the prognostic impact of the Epstein-Barr virus-encoded latent membrane protein-1 expression in Hodgkin's disease. British Journal of Cancer, 84, 1227-1234.
57. Goedert, J.J., Cote, T.R., Virgo, P., Scoppa, S.M., Kingma, D.W., Gail, M.H., Jaffe, E.S. & Biggar, R.J. (1998) Spectrum of AIDS-associated malignant disorders. Lancet, 351, 1833-1839.
58. Gottschalk, S., Edwards, O.L., Huls, M.H., Goltsova, T., Davis, A.R., Heslop, H.E. & Rooney, C.M. (2002) Generating CTL against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive Immunotherapy of EBV-associated malignancies. Blood, 31, 31.
59. Gulley, M.L., Eagan, P.A., Quintanilla-Martinez, L., Picado, A.L., Smir, B.N., Childs, C., Dunn, C.D., Craig, F.E., Williams, J.W., Jr & Banks, P.M. (1994) Epstein-Barr virus DNA is abundant and monoclonal in the Reed-Sternberg cells of Hodgkin's disease: association with mixed cellularity subtype and Hispanic American ethnicity. Blood, 83, 1595-1602.
60. Gulley, M.L., Glaser, S.L., Craig, F.E., Borowitz, M., Mann, R.B., Shema, S.J. & Ambinder, R.F. (2002) Guidelines for interpreting EBER in situ hybridization and LMP1 immunohistochemical tests for detecting Epstein-Barr virus in Hodgkin lymphoma. American Journal of Clinical Pathology, 117, 259-267.
61. Haque, T., Wilkie, G.M., Taylor, C., Amlot, P.L., Murad, P., Iley, A., Dombagoda, D., Britton, K.M., Swerdlow, A.J. & Crawford, D.H. (2002) Treatment of Epstein-Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells. Lancet, 360, 436-442.
62. Hartmann, F., Renner, C., Jung, W., da Costa, L., Tembrink, S., Held, G., Sek, A., Konig, J., Bauer, S., Kloft, M. & Pfreundschuh, M. (2001) Anti-CD16/CD30 bispecific antibody treatment for Hodgkin's disease: role of infusion schedule and costimulation with cytokines. Clinical Cancer Research, 7, 1873-1881.
63. Hartmann, P., Rehwald, U., Salzberger, B., Franzen, C., Sieber, M., Wohrmann, A. & Diehl, V. (2003) BEACOPP therapeutic regimen for patients with Hodgkin's disease and HIV infection. Annals of Oncology, 14, 1562-1569.
64. Henderson, S., Rowe, M., Gregory, C., Croom-Carter, D., Wang, F., Longnecker, R., Kieff, E. & Rickinson, A. (1991) Induction of bcl-2 expression by Epstein-Barr virus latent membrane protein 1 protects infected B cells from programmed cell death. Cell, 65, 1107-1115.
65. Herbst, H., Dallenbach, F., Hummel, M., Niedobitek, G., Pileri, S., Muller-Lantzsch, N. & Stein, H. (1991) Epstein-Barr virus latent membrane protein expression in Hodgkin and Reed-Sternberg cells. Proceedings of the National Academy of Sciences, United States of America, 88, 4766-4770.
66. Herbst, H., Steinbrecher, E., Niedobitek, G., Young, L.S., Brooks, L., Muller-Lantzsch, N. & Stein, H. (1992) Distribution and phenotype of Epstein-Barr virus-harboring cells in Hodgkin's disease. Blood, 80, 484-491.
67. Hjalgrim, H., Askling, J., Rostgaard, K., Hamilton-Dutoit, S., Frisch, M., Zhang, J.S., Madsen, M., Rosdahl, N., Konradsen, H.B., Storm, H.H. & Melbye, M. (2003) Characteristics of Hodgkin's lymphoma after infectious mononucleosis. New England Journal of Medicine, 349, 1324-1332.
68. Horning, S.J. (1998) Primary refractory Hodgkin's disease. Annals of Oncology, 9 (Suppl. 5), S97-S101.
69. Huen, D.S., Henderson, S.A., Croom-Carter, D. & Rowe, M. (1995) The Epstein-Barr virus latent membrane protein-1 (LMP1) mediates activation of NF-kappa B and cell surface phenotype via two effector regions in its carboxy-terminal cytoplasmic domain. Oncogene, 10, 549-560.
70. Jaffe, E.S., Harris, N.L., Stein, H. & Vardiman, J.W. (2001) Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. International Agency for Research on Cancer Press, Lyon.
71. Jarrett, R.F. (2002) Viruses and Hodgkin's lymphoma. Annals of Oncology, 13, 23-29.
72. Jarrett, A.F., Armstrong, A.A. & Alexander, E. (1996) Epidemiology of EBV and Hodgkin's lymphoma. Annals of Oncology, 7 (Suppl. 4), 5-10.
73. Jiwa, N.M., Oudejans, J.J., Bai, M.C., Van den Brule, A.J., Horstman, A., Vos, W., Van der Valk, P., Kluin, P.M., Walboomers, J.M. & Meijer, C.J. (1995) Expression of bcl-2 protein and transcription of the Epstein-Barr virus bcl-2 homologue BHRF-1 in Hodgkin's disease: implications for different pathogenic mechanisms. Histopathology, 26, 547-553.
74. Jungnickel, B., Staratschek-Jox, A., Brauninger, A., Spieker, T., Wolf, J., Diehl, V., Hansmann, M.L., Rajewsky, K. & Küppers, R. (2000) Clonal deleterious mutations in the IkappaBalpha gene in the malignant cells in Hodgkin's lymphoma. Journal of Experimental Medicine, 191, 395-402.
75. Kanzler, H., Küppers, R., Hansmann, M.L. & Rajewsky, K. (1996) Hodgkin and Reed-Sternberg cells in Hodgkin's disease represent the outgrowth of a dominant tumor clone derived from (crippled) germinal center B cells. Journal of Experimental Medicine, 184, 1495-1505.
76. Khanna, R. & Burrows, S.R. (2000) Role of cytotoxic T lymphocytes in Epstein-Barr virus-associated diseases. Annual Review of Microbiology, 54, 19-48.
77. Khanna, R., Burrows, S.R., Moss, D.J. & Silins, S.L. (1996) Peptide transporter (TAP-1 and TAP-2)-independent endogenous processing of Epstein-Barr virus (EBV) latent membrane protein 2A: implications for cytotoxic T-lymphocyte control of EBV-associated malignancies. Journal of Virology, 70, 5357-5362.
78. Khanna, R., Burrows, S.R., Steigerwald-Mullen, P.M., Moss, D.J., Kurilla, M.G. & Cooper, L. (1997) Targeting Epstein-Barr virus nuclear antigen 1 (EBNA1) through the class II pathway restores immune recognition by EBNA1-specific cytotoxic T lymphocytes: evidence for HLA-DM-independent processing. International Immunology, 9, 1537-1543.
79. Khanna, R., Tellam, J., Duraiswamy, J. & Cooper, L. (2001) Immunotherapeutic strategies for EBV-associated malignancies. Trends in Molecular Medicine, 7, 270-276.
80. Kim, S.H., Choi, E.Y., Shin, Y.K., Kim, T.J., Chung, D.H., Chang, S.I., Kim, N.K. & Park, S.H. (1998) Generation of cells with Hodgkin's and Reed-Sternberg phenotype through downregulation of CD99 (Mic2). Blood, 92, 4287-1295.
81. Kim, S.H., Shin, Y.K., Lee, I.S., Bae, Y.M., Sohn, H.W., Suh, Y.H., Ree, H.J., Rowe, M. & Park, S.H. (2000) Viral latent membrane protein 1 (LMP-1)-induced CD99 down-regulation in B cells leads to the generation of cells with Hodgkin's and Reed-Sternberg phenotype. Blood, 95, 294-300.
82. Kitagawa, N., Goto, M., Kurozumi, K., Maruo, S., Fukayama, M., Naoe, T., Yasukawa, M., Hino, K., Suzuki, T., Todo, S. & Takada, K. (2000) Epstein-Barr virus-encoded poly(A)(-) RNA supports Burkitt's lymphoma growth through interleukin-10 induction. European Molecular Biology Organization Journal, 19, 6742-6750.
83. Klitz, W., Aldrich, C.L., Fildes, N., Horning, S.J. & Begovich, A.B. (1994) Localization of predisposition to Hodgkin disease in the HLA class II region. American Journal of Human Genetics, 54, 497-505.
84. Knecht, H., McQuain, C., Martin, J., Rothenberger, S., Drexler, H.G., Berger, C., Bachmann, E., Kittler, E.L., Odermatt, B.F. & Quesenberry, P.J. (1996) Expression of the LMP1 oncoprotein in the EBV negative Hodgkin's disease cell line L-428 is associated with Reed-Sternberg cell morphology. Oncogene, 13, 947-953.
85. Kornacker, M., Jox, A., Vockerodt, M., Tesch, H., Bohlen, H., Diehl, V. & Wolf, J. (1999) Detection of a Hodgkin/Reed-Sternberg cell specific immunoglobulin gene rearrangement in the serum DNA of a patient with Hodgkin's disease. British Journal of Haematology, 106, 528-531.
86. Krappmann, D., Emmerich, F., Kordes, U., Scharschmidt, E., Dorken, B. & Scheidereit, C. (1999) Molecular mechanisms of constitutive NF-kappaB/Rel activation in Hodgkin/Reed-Sternberg cells. Oncogene, 18, 943-953.
87. Kruger, S., Schroers, R., Rooney, C.M., Gahn, B. & Chen, S.Y. (2003) Identification of a naturally processed HLA-DR-restricted T-helper epitope in Epstein-Barr virus nuclear antigen type 1. Journal of Immunotherapy, 26, 212-221.
88. Küppers, R. (2003) B cells under influence: transformation of B cells by Epstein-Barr virus. Nature Review Immunology, 3, 801-812.
89. Küppers, R., Klein, U., Schwering, I., Distler, V., Brauninger, A., Cattoretti, G., Tu, Y., Stolovitzky, G.A., Califano, A., Hansmann, M.L. & Dalla-Favera, R. (2003) Identification of Hodgkin and Reed-Sternberg cell-specific genes by gene expression profiling. Journal of Clinical Investigation, 111, 529-537.
90. Lee, S.P., Constandinou, C.M., Thomas, W.A., Croom-Carter, D., Blake, N.W., Murray, P.G., Crocker, J. & Rickinson, A.B. (1998) Antigen presenting phenotype of Hodgkin Reed-Sternberg cells: analysis of the HLA class I processing pathway and the effects of interleukin-10 on Epstein-barr virus-specific cytotoxic T-cell recognition. Blood, 92, 1020-1030.
91. Lei, K.I., Chan, L.Y., Chan, W.Y., Johnson, P.J. & Lo, Y.M. (2000) Quantitative analysis of circulating cell-free Epstein-Barr virus (EBV) DNA levels in patients with EBV-associated lymphoid malignancies. British Journal of Haematology, 111, 239-246.
92. Leoncini, L., Spina, D., Nyong'o, A., Abinya, O., Minacci, C., Disanto, A., De Luca, F., De Vivo, A., Sabattini, E., Poggi, S., Pileri, S. & Tosi, P. (1996) Neoplastic cells of Hodgkin's disease show differences in EBV expression between Kenya and Italy. International Journal of Cancer, 65, 781-784.
93. Levitskaya, J., Coram, M., Levitsky, V., Imreh, S., Steigerwald-Mullen, P.M., Klein, G., Kurilla, M.G. & Masucci, M.G. (1995) Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1. Nature, 375, 685-688.
94. Levitskaya, J., Sharipo, A., Leonchiks, A., Ciechanover, A. & Masucci, M.G. (1997) Inhibition of ubiquitin/proteasome-dependent protein degradation by the Gly-Ala repeat domain of the Epstein-Barr virus nuclear antigen 1. Proceedings of the National Academy of Sciences, United States of America, 94, 12616-12621.
95. Lin, C.L., Lo, W.F., Lee, T.H., Ren, Y., Hwang, S.L., Cheng, Y.F., Chen, C.L., Chang, Y.S., Lee, S.P., Rickinson, A.B. & Tam, P.K. (2002) Immunization with Epstein-Barr Virus (EBV) peptide-pulsed dendritic cells induces functional CD8+ T-cell immunity and may lead to tumor regression in patients with EBV-positive nasopharyngeal carcinoma. Cancer Research, 62, 6952-6958.
96. Mack, T.M., Cozen, W., Shibata, D.K., Weiss, L.M., Nathwani, B.N., Hernandez, A.M., Taylor, C.R., Hamilton, A.S., Deapen, D.M. & Rappaport, E.B. (1995) Concordance for Hodgkin's disease in identical twins suggesting genetic susceptibility to the young-adult form of the disease. New England Journal of Medicine, 332, 413-418.
97. MacMahon, B. (1966) Epidemiology of Hodgkin's disease. Cancer Research, 26, 1189-1201.
98. Maggio, E., van den Berg, A., Diepstra, A., Kluiver, J., Visser, L. & Poppema, S. (2002) Chemokines, cytokines and their receptors in Hodgkin's lymphoma cell lines and tissues. Annals of Oncology, 13 (Suppl. 1), 52-56.
99. Marafioti, T., Hummel, M., Foss, H.D., Laumen, H., Korbjuhn, P., Anagnostopoulos, I., Lammert, H., Demel, G., Theil, J., Wirth, T. & Stein, H. (2000) Hodgkin and reed-sternberg cells represent an expansion of a single clone originating from a germinal center B-cell with functional immunoglobulin gene rearrangements but defective immunoglobulin transcription. Blood, 95, 1443-1450.
100. Marks, D.I., Lush, R., Cavenagh, J., Milligan, D.W., Schey, S., Parker, A., Clark, F.J., Hunt, L., Yin, J., Fuller, S., Vandenberghe, E., Marsh, J., Littlewood, T., Smith, G.M., Culligan, D., Hunter, A., Chopra, R., Davies, A., Towlson, K. & Williams, C.D. (2002) The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation. Blood, 100, 3108-3114.
101. Marshall, M.A., Munro, L.R., Culligan, D.J., Barker, R.N. & Vickers, M.A. (2003a) Regulatory cell mediated immunosuppression in Hodgkin lymphoma. British Journal of Haematology, 121, abstract 143.
102. Marshall, N.A., Vickers, M.A. & Barker, R.N. (2003b) Regulatory T cells secreting EL-10 dominate the immune response to EBV latent membrane protein 1. Journal of Immunology, 170, 6183-6189.
103. Mehl, A.M., Fischer, N., Rowe, M., Hartmann, F., Daus, H., Trumper, L., Pfreundschuh, M., Muller-Lantzsch, N. & Grasser, F.A. (1998) Isolation and analysis of two strongly transforming isoforms of the Epstein-Barr-virus (EBV)-encoded latent membrane protein-1 (LMP1) from a single Hodgkin's lymphoma. International Journal of Cancer, 76, 194-200.
104. Miyashita, E.M., Yang, B., Babcock, G.J. & Thorley-Lawson, D.A. (1997) Identification of the site of Epstein-Barr virus persistence in vivo as a resting B cell. Journal of Virology, 71, 4882-4891.
105. Mueller, N., Evans, A., Harris, N.L., Comstock, G.W., Jellum, E., Magnus, K., Orentreich, N., Polk, B.F. & Vogelman, J. (1989) Hodgkin's disease and Epstein-Barr virus. Altered antibody pattern before diagnosis. New England Journal of Medicine, 320, 689-695.
106. Murray, R.J., Kurilla, M.G., Brooks, J.M., Thomas, W.A., Rowe, M., Kieff, E. & Rickinson, A.B. (1992) Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies. Journal of Experimental Medicine, 176, 157-168.
107. Murray, P.G., Constandinou, C.M., Crocker, J., Young, L.S. & Ambinder, R.F. (1998) Analysis of major histocompatibility complex class I, TAP expression, and LMP2 epitope sequence in Epstein-Barr virus-positive Hodgkin's disease. Blood, 92, 2477-2483.
108. Nalesnik, M.A., Randhawa, P., Demetris, A.J., Casavilla, A., Fung, J.J. & Locker, J. (1993) Lymphoma resembling Hodgkin disease after posttransplant lymphoproliferative disorder in a liver transplant recipient. Cancer, 72, 2568-2573.
109. Nerurkar, A.Y., Vijayan, P., Srinivas, V., Soman, C.S., Dinshaw, K.A., Advani, S.H., Magrath, I., Bhatia, K. & Naresh, K.N. (2000) Discrepancies in Epstein-Barr virus association at presentation and relapse of classical Hodgkin's disease: impact on pathogenesis. Annals of Oncology, 11, 475-478.
110. Ng, A.K., Bernardo, M.P., Weller, E., Backstrand, K.H., Silver, B., Marcus, K.C., Tarbell, N.J., Friedberg, J., Canellos, G.P. & Mauch, P.M. (2002) Long-term survival and competing causes of death in patients with early-stage Hodgkin's disease treated at age 50 or younger. Journal of Clinical Oncology, 20, 2101-2108.
111. Niedobitek, G., Pazolt, D., Teichmann, M. & Devergne, O. (2002) Frequent expression of the Epstein-Barr virus (EBV)-induced gene, EBI3, an IL-12 p40-related cytokine, in Hodgkin and Reed-Sternberg cells. Journal of Pathology, 198, 310-316.
112. Pallesen, G., Hamilton-Dutoit, S.J., Rowe, M. & Young, L.S. (1991) Expression of Epstein-Barr virus latent gene products in tumour cells of Hodgkin's disease. Lancet, 337, 320-322.
113. Parkin, D.M. & Muir, C.S. (1992) Cancer Incidence in Five Continents. Comparability and quality of data. Interational Agency for Research on Cancer Scientific Publications, 120, 45-173.
114. Peggs, K.S., Verfuerth, S., Pizzey, A., Khan, N., Guiver, M., Moss, P.A. & Mackinnon, S. (2003) Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines. Lancet, 362, 1375-1377.
115. Perkins, C.I., Morris, C.R., Wright, W.E. & Young, J.L. (1995) Cancer Incidence in Mortality in California by Detailed Race/Ethnicity, 1988/ 1992. California Department of Health Services Surveillance Section, Sacramento, CA.
116. Poppema, S., Potters, M., Emmens, R., Visser, L. & van den Berg, A. (1999) Immune reactions in classical Hodgkin's lymphoma. Seminars in Hematology, 36, 253-259.
117. Porter, D.L., Connors, J.M., Van Deerlin, V.M., Duffy, K.M., McGarigle, C., Saidman, S.L., Leonard, D.G. & Antin, J.H. (1999) Graft-versus-tumor induction with donor leukocyte infusions as primary therapy for patients with malignancies. Journal of Clinical Oncology, 17, 1234.
118. Portis, T., Dyck, P. & Longnecker, R. (2003) Epstein-Barr virus (EBV) LMP2A induces alterations in gene transcription similar to those observed in Reed-Sternberg cells of Hodgkin's lymphoma. Blood, 102, 4166-4178.
119. Rickinson, A. (2002) Epstein-Barr virus. Virus Research, 82, 109-113.
120. Rickinson, A.B. & Moss, D.J. (1997) Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection. Annual Reviews in Immunology, 15, 405-431.
121. Rickinson, A.B., Jarvis, J.E., Crawford, D.H. & Epstein, M.A. (1974) Observations on the type of infection by Epstein-Barr virus in peripheral lymphoid cells of patients with infectious mononucleosis. International Journal of Cancer, 14, 704-715.
122. Robinson, S.P., Goldstone, A.H., Mackinnon, S., Carella, A., Russell, N., de Elvira, C.R., Taghipour, G. & Schmitz, N. (2002) Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Blood, 100, 4310-4316.
123. Rooney, C.M., Roskrow, M.A., Suzuki, N., Ng, C.Y., Brenner, M.K. & Heslop, H. (1998) Treatment of relapsed Hodgkin's disease using EBV-specific cytotoxic T cells. Annals of Oncology, 9, S129-S132.
124. Roskrow, M.A., Suzuki, N., Gan, Y., Sixbey, J.W., Ng, C.Y., Kimbrough, S., Hudson, M., Brenner, M.K., Heslop, H.E. & Rooney, C.M. (1998) Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the treatment of patients with EBV-positive relapsed Hodgkin's disease. Blood, 91, 2925-2934.
125. Rowlings, P.A., Curtis, R.E., Passweg, J.R., Deeg, H.J., Socie, G., Travis, L.B., Kingma, D.W., Jaffe, E.S., Sobocinski, K.A. & Horowitz, M.M. (1999) Increased incidence of Hodgkin's disease after allogeneic Bone Marrow Transplantationation. Journal of Clinical Oncology, 17, 3122-3127.
126. Schmitz, N., Pfistner, B., Sextro, M., Sieber, M., Carella, A.M., Haenel, M., Boissevain, F., Zschaber, R., Muller, P., Kirchner, H., Lohri, A., Decker, S., Koch, B., Hasenclever, D., Goldstone, A.H. & Diehl, V. (2002) Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet, 359, 2065-2071.
127. Schnell, R., Staak, O., Borchmann, P., Schwartz, C., Matthey, B., Hansen, H., Schindler, J., Ghetie, V., Vitetta, E.S., Diehl, V. & Engert, A. (2002) A Phase I study with an anti-CD30 ricin A-chain immunotoxin (Ki-4.dgA) in patients with refractory CD30+ Hodgkin's and non-Hodgkin's lymphoma. Clinical Cancer Research, 8, 1779-1786.
128. Schwaller, J., Tobler, A., Niklaus, G., Hurwitz, N., Hennig, I., Fey, M.F. & Borisch, B. (1995) Interleukin-12 depression in human lymphomas and nonneoplastic lymphoid disorders. Blood, 85, 2182-2188.
129. Sherritt, M.A., Bharadwaj, M., Burrows, J.M., Morrison, L.E., Elliott, S.L., Davis, J.E., Kear, L.M., Slaughter, R.E., Bell, S.C., Galbraith, A.J., Khanna, R. & Moss, D.J. (2003) Reconstitution of the latent T-lymphocyte response to Epstein-Barr virus is coincident with long-term recovery from posttransplant lymphoma after adoptive immunotherapy. Transplantation, 75, 1556-1560.
130. Sing, A.P., Ambinder, R.F., Hong, D.J., Jensen, M., Batten, W., Petersdorf, E. & Greenberg, P.D. (1997) Isolation of Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes that lyse Reed-Sternberg cells: implications for immune-mediated therapy of EBV+ Hodgkin's disease. Blood, 89, 1978-1986.
131. Skinnider, B.F. & Mak, T.W. (2002) The role of cytokines in classical Hodgkin lymphoma. Blood, 99, 4283-4297.
132. Spina, M., Gabarre, J., Rossi, G., Fasan, M., Schiantarelli, C., Nigra, E., Mena, M., Antinori, A., Ammassari, A., Talamini, R., Vaccher, E., di Gennaro G. & Tirelli, U. (2002) Stanford V regimen and concomitant HAART in 59 patients with Hodgkin disease and HIV infection. Blood, 100, 1984-1988.
133. Staratschek-Jox, A., Kotkowski, S., Belge, G., Rudiger, T., Bullerdiek, J., Diehl, V. & Wolf, J. (2000) Detection of Epstein-Barr virus in Hodgkin-Reed-Sternberg cells : no evidence for the persistence of integrated viral fragments inLatent membrane protein-1 (LMP-1)-negative classical Hodgkin's disease. American Journal of Pathology, 156, 209-216.
134. Stark, G.L., Wood, K.M., Jack, F., Angus, B., Proctor, S.J. & Taylor, P.R. (2002) Hodgkin's disease in the elderly, a population-based study. British Journal of Haematology, 119, 432-440.
135. Steven, N.M., Leese, A.M., Annels, N.E., Lee, S.P. & Rickinson, A.B. (1996) Epitope focusing in the primary cytotoxic T cell response to Epstein-Barr virus and its relationship to T cell memory. Journal of Experimental Medicine, 184, 1801-1813.
136. Sweetenham, J.W., Carella, A.M., Taghipour, G., Cunningham, D., Marcus, R., Della Volpe, A., Linch, D.C., Schmitz, N. & Goldstone, A.H. (1999) High-dose therapy and autologous stem-cell transplantation for adult patients with Hodgkin's disease who do not enter remission after induction chemotherapy: results in 175 patients reported to the European Group for Blood and Marrow Transplantation. Lymphoma Working Party. Journal of Clinical Oncology, 17, 3101-3109.
137. Szmania, S., Galloway, A., Bruorton, M., Musk, P., Aubert, G., Arthur, A., Pyle, H., Hensel, N., Ta, N., Lamb, L., Jr., Dodi, T., Madrigal, A., Barrett, J., Henslee-Downey, J. & van Rhee, F. (2001) Isolation and expansion of cytomegalovirus-specific cytotoxic T lymphocytes to clinical scale from a single blood draw using dendritic cells and HLA-tetramers. Blood, 98, 505-512.
138. Tellam, J., Sherritt, M., Thomson, S., Tellam, R., Moss, D.J., Burrows, S.R., Wiertz, E. & Khanna, R. (2001) Targeting of EBNA1 for rapid intracellular degradation overrides the inhibitory effects of the Gly-Ala repeat domain and restores CD8+ T cell recognition. Journal of Biological Chemistry, 276, 33353-33360.
139. Tellam, J., Connolly, G., Webb, N., Duraiswamy, J. & Khanna, R. (2003) Proteasomal targeting of a viral oncogene abrogates oncogenic phenotype and enhances immunogenicity. Blood, 102, 4535-4540.
140. Timms, J.M., Bell, A., Flavell, J.R., Murray, P.G., Rickinson, A.B., Traverse-Glehen, A., Berger, F. & Delecluse, H.J. (2003) Target cells of Epstein-Barr-virus (EBV)-positive post-transplant lymphoproliferative disease: similarities to EBV-poritive Hodgkin's lymphoma. Lancet, 361, 217-223.
141. Tomita, Y., Ohsawa, M., Kanno, H., Hashimoto, M., Ohnishi, A., Nakanishi, H. & Aozasa, K. (1996) Epstein-Barr virus in Hodgkin's disease patients in Japan. Cancer, 77, 186-192.
142. Vaughan Hudson, B., Vaughan Hudson, G., Linch, D.C. & Anderson, L. (1994) Late mortality in young BNLI patients cured of Hodgkin's disease. Annals of Oncology, 5 (Suppl. 2), 65-66.
143. Voo, K.S., Fu, T., Heslop, H.E., Brenner, M.K., Rooney, C.M. & Wang, R.F. (2002) Identification of HLA-DP3-restricted peptides from EBNA1 recognized by CD4(+) T cells. Cancer Research, 62, 7195-7199.
144. Wagner, H.J., Schlager, F., Claviez, A. & Bucsky, P. (2001) Detection of Epstein-Barr virus DNA in peripheral blood of paediatric patients with Hodgkin's disease by real-time polymerase chain reaction. European Journal of Cancer, 37, 1853-1857.
145. Weinreb, M., Day, P.J., Niggli, F., Powell, J.E., Raafat, F., Hesseling, P.B., Schneider, J.W., Hartley, P.S., Tzortzatou-Stathopoulou, F., Khalek, E.R., Mangoud, A., El-Safy, U.R., Madanat, F., Al Sheyyab, M., Mpofu, C., Revesz, T., Rafii, R., Tiedemann, K., Waters, K.D., Barrantes, J.C., Nyongo, A., Riyat, M.S. & Mann, J.R. (1996) The role of Epstein-Barr virus in Hodgkin's disease from different geographical areas. Archives of Disease in Childhood, 74, 27-31.
146. Weiss, L.M., Chen, Y.Y., Liu, X.F. & Shibata, D. (1991) Epstein-Barr virus and Hodgkin's disease. A correlative in situ hybridization and polymerase chain reaction study. American Journal of Pathology, 139, 1259-1265.
147. Wilson, J.B., Bell, J.L. & Levine, A.J. (1996) Expression of Epstein-Barr virus nuclear antigen-1 induces B cell neoplasia in transgenic mice. European Molecular Biology Organization Journal, 15, 3117-3126.
148. Yates, J.L., Warren, N. & Sugden, B. (1985) Stable replication of plasmids derived from Epstein-Barr virus in various mammalian cells. Nature, 313, 812-815.
149. Yin, Y., Manoury, B. & Fahraeus, R. (2003) Self-inhibition of synthesis and antigen presentation by Epstein-Barr virus-encoded EBNA1. Science, 301, 1371-1374.
150. Yoshioka, M., Kikuta, H., Ishiguro, N., Ma, X. & Kobayashi, K. (2003) Unique Epstein-Barr virus (EBV) latent gene expression, EBNA promoter usage and EBNA promoter methylation status in chronic active EBV infection. Journal of General Virology, 84, 1133-1140.
151. Yotnda, P., Onishi, H., Heslop, H.E., Shayakhmetov, D., Lieber, A., Brenner, M. & Davis, A. (2001) Efficient infection of primitive hematopoietic stem cells by modified adenovirus. Gene Therapy, 8, 930-937.